Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.820
-0.240 (-5.91%)
Dec 20, 2024, 4:00 PM EST - Market closed
Grace Therapeutics Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 - 2015 |
Revenue | - | - | - | - | 0.2 | - | Upgrade
|
Cost of Revenue | - | - | - | - | 0.08 | - | Upgrade
|
Gross Profit | - | - | - | - | 0.12 | - | Upgrade
|
Selling, General & Admin | 7.29 | 6.68 | 8.28 | 6.58 | 6.66 | 8.46 | Upgrade
|
Research & Development | 8.72 | 4.59 | 9.93 | 5.56 | 4.17 | 15.97 | Upgrade
|
Operating Expenses | 16.01 | 11.28 | 18.21 | 12.14 | 10.84 | 24.44 | Upgrade
|
Operating Income | -16.01 | -11.28 | -18.21 | -12.14 | -10.72 | -24.44 | Upgrade
|
Interest Expense | - | - | - | - | -0.26 | -0.25 | Upgrade
|
Interest & Investment Income | 0.97 | 0.91 | 0.25 | 0.08 | 0.11 | 0.34 | Upgrade
|
Currency Exchange Gain (Loss) | -0.01 | -0.02 | -0.07 | -0.3 | -0.68 | -0 | Upgrade
|
Other Non Operating Income (Expenses) | 0.85 | -2.73 | 0.01 | 5.34 | -2.43 | -1.16 | Upgrade
|
EBT Excluding Unusual Items | -14.19 | -13.11 | -18.02 | -7.02 | -13.98 | -25.51 | Upgrade
|
Merger & Restructuring Charges | - | -1.49 | -33.51 | -3.2 | - | - | Upgrade
|
Asset Writedown | -0.09 | -0.09 | -0.44 | -0.25 | -5.7 | - | Upgrade
|
Pretax Income | -14.28 | -14.69 | -51.97 | -10.47 | -19.68 | -25.51 | Upgrade
|
Income Tax Expense | -2.67 | -1.83 | -9.54 | -0.65 | - | - | Upgrade
|
Net Income | -11.61 | -12.85 | -42.43 | -9.82 | -19.68 | -25.51 | Upgrade
|
Net Income to Common | -11.61 | -12.85 | -42.43 | -9.82 | -19.68 | -25.51 | Upgrade
|
Shares Outstanding (Basic) | 12 | 10 | 7 | 6 | 2 | 2 | Upgrade
|
Shares Outstanding (Diluted) | 12 | 10 | 7 | 6 | 2 | 2 | Upgrade
|
Shares Change (YoY) | 54.23% | 28.16% | 21.09% | 148.46% | 40.25% | 55.80% | Upgrade
|
EPS (Basic) | -1.01 | -1.35 | -5.71 | -1.60 | -7.96 | -14.48 | Upgrade
|
EPS (Diluted) | -1.01 | -1.35 | -5.71 | -1.60 | -7.96 | -14.48 | Upgrade
|
Free Cash Flow | -11.84 | -12.36 | -15.93 | -17.23 | -14.39 | -23.27 | Upgrade
|
Free Cash Flow Per Share | -1.03 | -1.30 | -2.14 | -2.81 | -5.82 | -13.21 | Upgrade
|
Gross Margin | - | - | - | - | 61.22% | - | Upgrade
|
Operating Margin | - | - | - | - | -5467.35% | - | Upgrade
|
Profit Margin | - | - | - | - | -10039.80% | - | Upgrade
|
Free Cash Flow Margin | - | - | - | - | -7340.82% | - | Upgrade
|
EBITDA | -16 | -11.27 | -18.08 | -11.22 | -9.79 | -22.12 | Upgrade
|
D&A For EBITDA | 0.01 | 0.01 | 0.12 | 0.92 | 0.92 | 2.32 | Upgrade
|
EBIT | -16.01 | -11.28 | -18.21 | -12.14 | -10.72 | -24.44 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.